Role of common human TRIM5α variants in HIV-1 disease progression

BackgroundThe retroviral restriction factor tripartite motif protein (TRIM)5α, is characterized by marked amino acid diversity among primates, including specific clusters of residues under positive selection. The identification of multiple non-synonymous changes in humans suggests that TRIM5α variants might be relevant to retroviral pathogenesis. Previous studies have shown that such variants are unlikely to modify susceptibility to HIV-1 infection, or the course of early infection. However, the longterm effect of carrying Trim5α variants on disease progression in individuals infected with HIV-1 has not previously been investigated.MethodsIn a cohort of 979 untreated individuals infected with HIV-1 with median follow up 3.2 years and 9,828 CD4 T cell measurements, we analysed common amino acid variations: H43Y, V112F, R136Q, G249D, and H419Y. The rate of CD4 T cell decline before treatment was used as the phenotype. In addition, we extended previous work on the in vitro susceptibility of purified donor CD4 T cells (n = 125) to HIV-1 infection, and on the susceptibility of HeLa cells that were stably transduced with the different TRIM5 variants. Haplotypes were analysed according to the most parsimonious evolutionary structure, where two main human TRIM5α groups can be defined according to the residue at amino acid 136. Humans present both Q136 and R136 at similar frequency, and additional TRIM5α amino acid variants are almost exclusively derived from R136-carrying haplotypes.ResultsWe observed modest differences in disease progression for evolutionary branches carrying R136-derived haplotypes, and with the non-synonymous polymorphisms G249D and H419Y. In vitro analysis of susceptibility of donor CD4 T cells, and of the various transduced HeLa cell lines supported the absence of significant differential restriction of HIV-1 infection by the various huTRIM5α alleles.ConclusionCommon human variants of TRIM5α have no effect or modest effect on HIV-1 disease progression. These variants occur at sites conserved throughout evolution, and are remote from clusters of positive selection in the primate lineage. The evolutionary value of the substitutions remains unclear.

[1]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[2]  G. Haughton.  SOME CELL‐BOUND, SPECIES‐SPECIFIC ANTIGENS OF MOUSE ASCITES‐TUMOR CELLS , 1962 .

[3]  D. Cameron,et al.  Immunochemotherapy of Cancer with Chlorambucil-carrying Antibody , 1972, British medical journal.

[4]  S. Nisole,et al.  TRIM family proteins: retroviral restriction and antiviral defence , 2005, Nature Reviews Microbiology.

[5]  Jonathan P. Stoye,et al.  A Single Amino Acid Change in the SPRY Domain of Human Trim5α Leads to HIV-1 Restriction , 2005, Current Biology.

[6]  J. Beckmann,et al.  Use of a Combined Ex Vivo/In Vivo Population Approach for Screening of Human Genes Involved in the Human Immunodeficiency Virus Type 1 Life Cycle for Variants Influencing Disease Progression , 2005, Journal of Virology.

[7]  M. Cloyd,et al.  Polymorphic human gene(s) determines differential susceptibility of CD4 lymphocytes to infection by certain HIV-1 isolates. , 1991, Virology.

[8]  J. Sodroski,et al.  The B30.2(SPRY) Domain of the Retroviral Restriction Factor TRIM5α Exhibits Lineage-Specific Length and Sequence Variation in Primates , 2005, Journal of Virology.

[9]  J. Sodroski,et al.  Species-Specific Variation in the B30.2(SPRY) Domain of TRIM5α Determines the Potency of Human Immunodeficiency Virus Restriction , 2005, Journal of Virology.

[10]  C. M. Owens,et al.  The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.

[11]  G. Towers.  Restriction of retroviruses by TRIM5α , 2006 .

[12]  Alessandro Guffanti,et al.  The tripartite motif family identifies cell compartments , 2001, The EMBO journal.

[13]  Sara L. Sawyer,et al.  High-Frequency Persistence of an Impaired Allele of the Retroviral Defense Gene TRIM5α in Humans , 2006, Current Biology.

[14]  Joseph Sodroski,et al.  Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. B. Amos,et al.  Passive immunity in mice against C57BL leukosis E.L. 4 by means of iso-immune serum. , 1956, Cancer research.

[16]  John Bui,et al.  Genetic Association of the Antiviral Restriction Factor TRIM5α with Human Immunodeficiency Virus Type 1 Infection , 2006, Journal of Virology.

[17]  Michael Emerman,et al.  Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Telenti,et al.  Patterns of evolution of host proteins involved in retroviral pathogenesis , 2006, Retrovirology.